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Abstract
Diets	low	in	methionine	extend	lifespan	of	rodents,	though	through	unknown	mech‐
anisms. Glycine can mitigate methionine toxicity, and a small prior study has sug‐
gested	 that	 supplemental	 glycine	 could	 extend	 lifespan	 of	 Fischer	 344	 rats.	 We	
therefore evaluated the effects of an 8% glycine diet on lifespan and pathology of 
genetically heterogeneous mice in the context of the Interventions Testing Program. 
Elevated	glycine	led	to	a	small	(4%–6%)	but	statistically	significant	lifespan	increase,	
as	well	as	an	 increase	 in	maximum	 lifespan,	 in	both	males	 (p	=	0.002)	and	 females	
(p	<	0.001).	Pooling	across	sex,	glycine	increased	lifespan	at	each	of	the	three	inde‐
pendent sites, with significance at p = 0.01, 0.053, and 0.03, respectively. Glycine‐
supplemented females were lighter than controls, but there was no effect on weight 
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1  | INTRODUC TION
Experiments	 to	 find	drugs	or	nutritional	 supplements	 that	can	ex‐
tend healthy lifespan in mice have four main goals. First, they pro‐
vide new models for testing the idea that interventions can retard 
multiple aspects of age‐dependent decline, including lethal illnesses 
and changes that impair health but seldom lead to death. Second, 
they give specific biochemical and physiological clues as to the na‐
ture of processes that regulate the pace of age‐dependent decline 
in	multiple	systems.	Lifespan	extension	and	health	preservation	 in	
rapamycin‐treated mice, for example, have prompted valuable stud‐
ies into the role of mTOR, the target of rapamycin, in normal mice 
and in mice with unusual susceptibility to organ‐specific illnesses 
(Harrison	 et	 al.,	 2009;	Miller	 et	 al.,	 2014;	Wilkinson	 et	 al.,	 2012).	
Third, they help guide the search for additional interventions with 
potential beneficial effects. Beneficial effects of acarbose, which in‐
hibits	postprandial	glucose	spikes,	can,	 for	example,	motivate	new	
studies	of	drugs	that	also	modulate	glucose	transients.	Lastly,	data	
on longevity and health outcomes in mice can serve to guide and 
inspire parallel searches for interventions that might, hypothetically, 
postpone multiple aspects of age‐related decline in humans.
The	NIA	Interventions	Testing	Program	(ITP)	has	to	date	reported	
on four drugs with consistent major effects on mouse lifespan in one 
or both sexes and found evidence for significant but less dramatic 
effect of four other drugs. Rapamycin, started at 9 months of age, 
was found to increase median lifespan by as much as 26% in females 
and 23% in males, and to retard many aspects of age‐related patho‐
logical	change	(Harrison	et	al.,	2009;	Miller	et	al.,	2014).	Surprisingly,	
similarly strong lifespan effects were seen even in mice not given 
rapamycin	until	20	months	of	age	(Harrison	et	al.,	2009).	Acarbose	
can lead to an increase of 22% in median lifespan in male mice, and 
to	a	 significant,	but	 smaller,	5%	 increase	 in	 female	mice	 (Harrison,	
2014;	Strong,	2016).	Both	rapamycin	and	acarbose	improve	longev‐
ity in the oldest age‐groups, as indicated by a statistical test that 
compares the proportion of control and drug‐treated mice surviving 
to	the	90th	percentile	age	of	the	joint	distribution,	the	Wang/Allison	
test	 (Wang,	 Li,	 Redden,	 Weindruch,	 &	 Allison,	 2004).	 Acarbose	
produces significant longevity increases, including survival to the 
90th percentile, in both sexes, when started as late as 16 months 
of	 age	 (Strong,	 2016).	 A	 third	 drug,	 17‐α‐estradiol	 (17aE2),	 a	 non‐
feminizing	congener	of	the	well‐known	estrogen	17‐β‐estradiol, in‐
creases	lifespan	of	male	mice	by	19%	(Harrison,	2014;	Strong,	2016)	
and has a significant effect on survival to the 90th percentile age, 
but	has	no	significant	effect	on	female	mice.	Male	mice	given	17aE2	
live significantly longer than female mice whether or not the females 
have	 been	 exposed	 to	 17aE2.	 Lastly,	NDGA	 (nordihydroguaiaretic	
acid)	has	been	shown	to	increase	lifespan	of	male	mice	only,	with	an	
increase of 12% in median in two independent experimental groups 
(Strong,	2016;	Strong	et	al.,	2008),	without	a	significant	effect	in	fe‐
male mice. Nordihydroguaiaretic acid, at the doses used, did not lead 
to significant changes in survival to the 90th percentile age.
Of	the	other	agents	tested	so	far	by	the	ITP,	four	(methylene	blue,	
aspirin,	Protandim,	and	green	tea	extract	[GTE])	provided	some	evi‐
dence	for	possible	health	benefits.	Methylene	blue	(Harrison,	2014)	
led	to	a	significant	(p	=	0.004)	increase	in	maximum	lifespan	that	was	
limited to females and was not accompanied by alteration in median. 
Aspirin	produced	an	8%	increase	 in	median	 lifespan	(p	=	0.01)	that	
was seen only in male mice, with no significant change in maximal 
lifespan	by	the	Wang/Allison	test	(Strong	et	al.,	2008).	Protandim,	an	
inducer of the stress‐resistance factor Nrf2, led to a 7% increase in 
median	lifespan	in	male	mice	(Strong,	2016),	but	there	was	no	effect	
in females, no effect on maximum lifespan in either sex, and a dra‐
matic site‐to‐site variance, with strong lifespan effects seen only at 
the	University	of	Texas	Health	Science	Center	at	San	Antonio	(UT)	
but	not	at	 the	 Jackson	Laboratory	 (TJL)	or	University	of	Michigan	
(UM)	sites.	Green	tea	extract	(Strong	et	al.,	2013)	did	not	show	a	sig‐
nificant effect by our standard analyses in either sex, but may have 
conferred some benefit, in females, against early and mid‐life deaths 
(p	=	0.03	by	Wilcoxon–Breslow	test,	which	gives	greater	weight	to	
early	than	to	later	deaths).
Diets low in the amino acid methionine have been shown to 
extend	 median	 and	 maximum	 lifespan	 in	 rats	 (Orentreich,	 1993;	
Richie	et	al.,	1994;	Zimmerman,	2003)	and	in	mice	(Brown‐Borg	et	
al.,	2014;	Miller	et	al.,	2005;	Sun,	2009),	although	it	is	not	yet	clearly	
in	males.	End‐of‐life	necropsies	suggested	that	glycine‐treated	mice	were	less	likely	
than	controls	to	die	of	pulmonary	adenocarcinoma	(p	=	0.03).	Of	the	40	varieties	of	
incidental pathology evaluated in these mice, none were increased to a significant 
degree by the glycine‐supplemented diet. In parallel analyses of the same cohort, we 
found	no	benefits	from	TM5441	(an	inhibitor	of	PAI‐1,	the	primary	inhibitor	of	tissue	
and	urokinase	plasminogen	activators),	inulin	(a	source	of	soluble	fiber),	or	aspirin	at	
either of two doses. Our glycine results strengthen the idea that modulation of die‐
tary amino acid levels can increase healthy lifespan in mice, and provide a foundation 
for further investigation of dietary effects on aging and late‐life diseases.
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established if diets deficient in other single amino acids might also 
lead	 to	 similar	 benefits.	 As	 a	 practical	 matter,	 interventions	 that	
involve supplementation of specific nutrients would be easier to 
test, in humans or mice, than diets that require depletion of specific 
compounds. Glycine plays a special role in methionine metabolism, 
serving as the only acceptor for methyl groups, through action of 
glycine‐N‐methyl	 transferase	 (GNMT),	 the	key	enzyme	 in	 the	only	
pathway	 for	 methionine	 clearance	 in	 mammals	 (Luka,	 Mudd,	 &	
Wagner,	2009).	Methionine	toxicity	can	be	blocked	by	dietary	gly‐
cine	(Luka	et	al.,	2009),	consistent	with	the	notion	that	GNMT	is	the	
principal effector of methionine clearance, at least at toxic levels. 
These data suggest that excess dietary glycine might depress methi‐
onine levels and thus mimic some of the benefits of a low methionine 
diet. Glycine‐supplemented diets have been reported to produce an‐
ticancer	and	anti‐inflammatory	effects	 in	rodents	 (Alarcon‐Aguilar,	
2008;	Wang	et	al.,	2013;	Zhong	et	al.,	2003)	and	to	provide	benefits	
in	humans	with	type	II	diabetes	during	a	3‐month	trial	(Cruz,	2008).	A	
small study using glycine supplementation in Fisher 344 rats showed 
significant	lifespan	extension	at	levels	of	8%,	12%,	and	20%	(Brind,	
2011),	although	the	higher	glycine	levels	led	to	weight	loss	compared	
to	 control	 rats.	Maximum	 lifespan,	evaluated	by	 the	Wang/Allison	
method,	was	significantly	increased	(p	=	0.03)	only	at	the	8%	supple‐
mentation level. In this earlier experiment, glycine treatment did not 
elevate plasma methionine levels, suggesting that the effect was not 
due	to	minimizing	methionine	toxicity,	but	to	some	other,	unknown,	
mechanism.
We	have	now	conducted	a	lifespan	trial	of	glycine	supplementa‐
tion in a large group of genetically heterogeneous male and female 
mice, and report here that 8% glycine leads to significant increases in 
longevity in both sexes and at each of three independent test sites. 
In the same annual cohort, we found no alteration of lifespan in mice 
treated	with	aspirin	 (60	or	200	ppm),	 inulin	 (600	ppm),	or	TM5441	
(an	inhibitor	of	plasminogen	activator	inhibitor	1;	used	at	60	ppm.).
2  | RESULTS
2.1 | Increased longevity in male and female mice
Mice	given	supplemental	glycine	as	8%	of	their	diet	by	weight,	
from age 9 months, survived significantly longer than controls. 
Figure 1 shows survival curves separately for males and for 
females, as well as the survival curve for both sexes pooled 
together. Our principal statistical criterion, as in earlier ITP stud‐
ies,	 is	the	log‐rank	test	evaluated	separately	for	each	sex	(with	
stratification	 for	 site).	 As	 shown	 in	 Table	 1,	 p = 0.006 for fe‐
males and p	=	0.002	for	male	mice	by	this	criterion.	When	males	
and	females	are	combined,	the	log‐rank	test	gives	p = 0.00004 
with stratification for site and sex. The effect on median lifes‐
pan	is	small:	Median	survival	age	increases	only	3%	in	each	sex,	
calculated	as	 the	average	change	across	 the	three	sites.	When	
all the data are pooled for each sex, the change in median is 
4% in females and 6% in males. The average increase in the age 
at which 90% of the mice have died is 2% for females and 6% 
for males, calculated as the mean of this value among the three 
sites. Our statistical criterion for questions about “maximum 
lifespan”	is	the	test	proposed	by	Wang	and	Allison	(Wang	et	al.,	
2004),	which	compares	the	number	of	mice	 in	each	group	that	
remains alive at the age at which 90% of the mice in the pooled 
life table have died. By this test, p = 0.7 for females, p = 0.0005 
for males, and p = 0.006 for the combination of males and fe‐
males.	We	conclude	that	8%	glycine	diet	causes	a	small	lifespan	
extension in both sexes, with late‐life effects seen at least in 
males.
The site‐specific data in Table 1 show that glycine caused an 
increase in lifespan at each site, with p = 0.013, p = 0.053, and 
p	=	0.026	at	TJL,	UM,	and	UT,	respectively,	when	male	and	female	
data	are	combined.	The	effect	was	stronger	for	females	at	TJL	and	
stronger	for	males	at	UT	in	this	experiment.
The glycine‐supplemented diet led to lower weights in female, 
but not in male, mice, as shown in Figure 2. By 12 months of age, 
that is, 3 months after initial exposure to the high glycine diet, fe‐
male mice were significantly lighter in weight than control animals 
(2.6	g,	equivalent	 to	7%	of	control	weight).	Glycine‐treated	female	
mice were 10% lighter than controls at 18 months, and 9% lighter at 
24 months, in each case significantly lower than in control females. 
Although	 it	 is	possible	that	diminished	food	 intake,	and	thus	some	
form of caloric restriction, may have affected health in glycine‐
treated	 females,	 this	 explanation	 seems	 unlikely	 to	 apply	 to	male	
mice, in which lifespan effects were equivalent and in which the diet 
did not alter weight trajectory.
F I G U R E  1  Survival	curves	for	glycine‐treated	mice,	pooled	across	sites.	Each	symbol	represents	one	mouse.	p‐values calculated by log‐
rank	test,	stratified	by	site	(for	panels	with	single‐sex	data)	or	by	both	site	and	sex	(for	the	panel	in	which	both	sexes	are	combined.)
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2.2 | End‐of‐life pathology
Mice	 in	 the	 glycine	 and	 control	 groups	were	 selected	 (by	 random	
numbers)	for	necropsy	analysis.	Tissue	sections	were	evaluated	by	a	
veterinary	pathologist	(JMS)	who	was	unaware	of	group	assignment.	
“Cause of death” diagnoses are summarized in Table 2. Of the 119 
specimens submitted, 8 were too severely autolyzed to be evalu‐
ated, and another 11 showed advanced autolysis but with evidence 
of	lethal	neoplasm	(details	in	Note	d	of	Table	2).	Of	these	19	autolysis	
cases,	15	came	from	a	single	site	(TJL),	so	TJL	cases	are	somewhat	
under‐represented in the remainder of the table. Of the 100 non‐
autolyzed	cases	(53	controls	and	47	glycine‐treated),	a	presumptive	
cause of death could be inferred in 81; the other 19 included 4 in 
which	multiple	potentially	fatal	diseases	were	present	(see	Note	c	in	
Table	2).	and	15	in	which	no	lesion	or	set	of	lesions	was	judged	to	be	
clearly responsible for the death of the animal.
In	 the	81	 cases	 in	which	 a	 likely	 cause	of	death	was	 assigned,	
glycine‐treated	mice	were	significantly	less	likely	than	controls	to	die	
of	pulmonary	adenocarcinoma	limited	to	the	lung	(p	=	0.03).	This	is	a	
lesion	that	is	more	often	seen	in	males	(seven	cases)	than	in	females	
(four	cases).	 In	addition,	we	noted	 that	adenocarcinoma	 limited	 to	
the	lung,	as	a	cause	of	death,	was	seen	frequently	at	TJL	(five	cases)	
and	at	UT	(five	cases)	but	rarely	at	UM	(one	case);	we	do	not	under‐
stand the reason for this site‐specific effect. Cases with lethal meta‐
static	carcinoma,	with	an	unknown	primary	source,	were	somewhat	
more common in the glycine group, but the difference did not reach 
statistical	significance	(p	=	0.098).	Some	of	these	may	have	had	lung	
or liver as a primary source, which might be evaluated by additional 
immunohistochemical methods.
In addition to evaluation of cause of death, the pathologist noted 
“incidental” lesions that were present at time of death but were not 
thought to be sufficiently severe to have led to death or terminal 
morbidity. Supporting Information Table S2 lists 12 lesions that were 
evaluated on a graded scale, and Supporting Information Table S3 
lists the 28 lesions that were listed as present or absent. There were 
no significant differences between control and glycine‐treated mice 
for any of these conditions.
2.3 | Aspirin, inulin, and TM5441 did not lead to 
lifespan effects
Many	interventions	proposed	and	accepted	by	the	ITP	for	longevity	
testing do not lead to increased lifespan, and ITP policy is to report 
these	negative	effects	for	all	compounds	tested.	Using	the	same	con‐
trol mice that were evaluated in the glycine experiment, we evaluated 
the	possible	effects	of	aspirin	(at	doses	of	60	and	200	ppm),	inulin	(at	
600	ppm),	and	TM5441,	an	inhibitor	of	PAI‐1,	used	at	60	ppm.	Each	
of	these	was	given	to	the	mice	starting	at	age	11	months.	Mice	were	
tested at all three sites in roughly equal numbers, as in the glycine 
F I G U R E  2  Weights	at	6,	12,	18,	and	24	months	for	glycine‐
treated mice, pooled across sites. Symbols show mean values. For 
controls, N ~ 96, 91, 83, 70 of each sex at each site, at the ages of 6, 
12, 18, and 24 months, respectively, and N for each group of glycine 
mice is about 50% of the number of controls. SEM	values	(not	
shown)	are	<1	g	for	each	age/treatment	group,	except	SEM = 1.6 g 
for glycine‐treated male mice at 24 months. Drug effect was 
evaluated	by	a	two‐factor	ANOVA	(site,	drug,	with	interaction	
term).	The	effect	of	glycine	was	p > 0.4 for males at each age. For 
females, p < 0.004 at ages 12, 18, and 24 months, as indicated by 
the	asterisks.
TA B L E  2   Summary of cause of death diagnoses
Cause of death Controls Glycine p‐value
Hemangiosarcoma 2 1
Hepatocellular	carcinoma 4 3
Lung	adenocarcinoma 9 2 0.03
Mammary	adenocarcinoma 1 2
Metastatic	carcinoma 1 5 0.098
Neoplasm	(other)a  2 2
Hematopoietic	neoplasia	(Round	
cell	tumor,	RCT)b 
12 11
Sarcoma	(other) 2 2
Soft tissue sarcoma 3 5
Amyloidosis 1 0
Atrial	thrombosis 2 3
Endometritis/metritis 2 0
Hepatic	necrosis 0 1
Nephritis 2 1
Multiple	processesc  3 1
Open 7 8
Total	(not	autolysis) 53 47
Autolysis 4 4
Autolysis	(likely	neoplasm)d  2 9 0.03
aHarderian	gland	adenocarcinoma;	a	necrotic,	hemorrhagic,	and	throm‐
bosed large subcutaneous neoplasm; a multifocal thoracic neoplasm 
with characteristics of both sarcoma and carcinoma; and a liver liposar‐
coma. b17 probably lymphomas; 6 probably histiocytic sarcomas; immu‐
nohistochemistry not performed. c1 severe amyloidosis and lung 
adenocarcinoma; 1 pituitary adenoma and atrial thrombosis; 1 lung ade‐
nocarcinoma and stomach squamous cell carcinoma; and 1 RCT and pitu‐
itary adenoma. d7	 likely	 to	 be	 hematopoietic	 (RCT);	 1	 hepatocellular	
carcinoma, 1 lung carcinoma, 1 sarcoma, and 1 hemangiosarcoma. 
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protocol.	As	shown	in	Figure	3	and	Supporting	Information	Table	S4,	
none of these treatments led to a significant alteration in longevity 
in	male	or	female	mice,	either	by	our	principal	criterion	the	log‐rank	
test,	 or	when	 evaluated	 by	 the	Wang/Allison	method	 at	 the	90th	
percentile. None of these agents had any significant effect on weight 
of	male	mice	(not	shown).	Weight	of	female	mice	was	unaffected	by	
aspirin	or	 inulin,	but	 female	mice	treated	by	TM5441	were	signifi‐
cantly heavier than control females at ages 12, 18, and 24 months 
(p	<	0.02	at	each	age;	data	not	shown).
2.4 | Assessment of drug and glycine levels in 
treated mice
Four batches of food containing supplemental glycine were evalu‐
ated for glycine content, with an average value of 7.1%, which is 
88% of the nominal expected level of 8% glycine. In a pilot experi‐
ment,	UM‐HET3	mice	were	given	a	glycine‐supplemented	diet	from	
10	months	 of	 age	 for	 a	 period	 of	 12	weeks.	 Serum	 levels	 of	 gly‐
cine in these glycine‐treated mice were 54 ± 18 μg/ml	 (mean	±	SD; 
N	=	4),	 and	 thus	 sixfold	 higher	 than	 glycine	 levels	 of	 control	mice,	
which were 9 ± 0.9 μg/ml	 (N	=	4).	 Similarly,	 liver	 levels	 of	 glycine	
were 1,200 ± 700 ng/mg in the treated mice, fourfold higher than 
in	controls	(290	±	40	ng/mg).	A	second	experiment	using	a	separate	
set of mice produced similar results: 85 versus 14 μg/ml in serum 
and 1,900 versus 335 ng/mg in liver. The correlation between serum 
and liver glycine values in the glycine‐fed mice had R2 = 0.94; mice 
with high serum glycine levels were also relatively high in their liver 
glycine content. Thus, glycine supplementation of food led to an in‐
crease in this amino acid in both serum and liver tissue.
Aspirin	and	its	breakdown	product	salicylic	acid	(SA)	were	mea‐
sured in three independent batches of food pellets, and the sum 
of	[aspirin	plus	SA]	was	found	to	be	83%	of	expected	in	the	pellets	
nominally containing 60 ppm, and 93% of expected levels in pellets 
nominally	 containing	 200	ppm.	 In	 a	 pilot	 experiment,	 UM‐HET3	
mice	were	given	chow	containing	aspirin	 for	11	weeks,	 starting	at	
6	months	of	age.	Aspirin	is	quickly	converted	to	SA	once	absorbed	
in	the	small	intestine,	and	mean	serum	levels	of	SA	in	the	mice	given	
60 ppm were 1.21 ± 1.03 μg/ml	 (mean	±	SD for N	=	17),	 and	 were	
4.1	±	4.4	in	mice	given	200	ppm	(N	=	21).	SA	levels	in	mice	fed	con‐
trol chow were consistently less than the detection limit of 0.15 μg/
ml.
Three	 batches	 of	 food	were	 tested	 for	 levels	 of	 TM5441,	 and	
the mean level of drug was 85% of the nominal value. Serum levels 
of	TM5441	were	198	ng/ml	(N = 7, SD	=	71)	when	mice	were	given	
chow	 containing	 TM5441	 for	 11	weeks	 starting	 at	 six	 months	 of	
age.	As	expected,	serum	from	control	mice	did	not	contain	detect‐
able	levels	of	TM5441	and	is	thus	below	the	standard	curve	limit	of	
1.6 ng/ml.
3  | DISCUSSION
Our most interesting new finding is that glycine‐supplemented diets 
extend	 lifespan	of	male	and	 female	UM‐HET3	mice,	 including	 sig‐
nificant benefits in lifespan to mice at the 90th percentile age. This 
supplementation leads to significant effects at each of the three test 
sites.	 The	 result	 is	 consistent	 with	 an	 earlier	 report	 (Brind,	 2011)	
showing	 a	 beneficial	 effect	 of	 glycine	 on	 lifespan	 (including	maxi‐
mal	lifespan)	in	small	groups	of	Fisher	344	rats.	The	effect	in	mice,	
although consistent with this prior rat study, is quite small and does 
not	much	 alter	median	 survival	 age.	We	 speculate	 that	 variations	
in this protocol, for example, in which glycine supplementation is 
started earlier or terminated once mice are fully grown, might have 
improved effects on health and lifespan.
Pathology	 assessment	 showed	 that	 UM‐HET3	 mice	 at	 end	 of	
life have a wide variety of age‐related lesions similar to those identi‐
fied	in	previous	longitudinal	studies	in	mice	(Harrison,	2014;	Snyder,	
Ward,	&	Treuting,	 2016).	 Incidental	 degenerative	 lesions,	 presum‐
ably related to aging but not a primary cause of death, occurred in 
all major organs examined, but did not appear to be influenced by 
F I G U R E  3  Survival	curves	for	mice	treated	with	aspirin,	inulin,	or	TM5441,	pooled	across	sites.	Left	panel:	females,	pooled	across	sites.	
Right panel: males, pooled across sites
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dietary glycine supplementation. Thus, there is no evidence from 
this	 work	 that	 glycine	 supplementation	 impairs	 health.	 Autolysis	
of organs secondary to carcass preservation technique and post‐
mortem autolysis in animals found dead complicated the scoring 
of	degenerative	 lesions	in	many	organs.	A	cross‐sectional	study,	 in	
which mice within a treatment cohort are euthanized and promptly 
subjected to necropsy with organ removal can be compared with a 
control cohort at the same time point, might show treatment differ‐
ences, though such a design provides little information about cause 
of death and tends to underestimate the incidence of lesions that 
lead	to	death	quickly	(Wolf,	Giddens,	&	Martin,	1988).
Of the 81 cases in which a presumptive cause of death was de‐
termined,	71	(88%)	died	as	the	result	of	neoplasia,	which	 is	similar	
to	previous	studies	(Harrison,	2014;	Lipman,	2004;	Miller	&	Chrisp,	
2002).	Dietary	glycine	had	no	effect	on	these	causes	of	death,	ex‐
cept for pulmonary adenocarcinoma, where only two mice died in 
the glycine‐supplemented cohort, compared to nine dying from this 
cancer	type	in	mice	fed	the	control	diet	(p	=	0.03).	If	one	includes	the	
two	mice	(one	in	each	group)	in	which	pulmonary	adenocarcinoma	
was considered to be a contributing cause of death, the difference 
in proportion reaches p = 0.06. Pulmonary adenomas were also seen 
more	frequently	in	control	animals	(a	total	of	12	neoplasms	in	nine	
mice)	 compared	 to	 glycine‐treated	 animals	 (a	 total	 of	 seven	 neo‐
plasms	in	seven	mice),	although	the	difference	between	groups	was	
not statistically significant. Several mice, especially in the glycine 
group, had metastatic carcinomas which affected the lung in addi‐
tion to a variety of other organs. Immunohistochemistry and other 
testing to better characterize the tissue of origin of these neoplasms 
were not performed, but one or more of these neoplasms may have 
arisen from the lung. There was no significant difference between 
the control and glycine groups when all carcinomas involving the 
lung, including metastatic neoplasms, were considered. Cross‐sec‐
tional studies in which neoplasms are potentially identified at an 
earlier stage may help define whether glycine exerts a protective 
effect	on	the	development	of	pulmonary	carcinoma.	Hematopoietic	
neoplasms	(round	cell	tumors)	were	also	a	common	cause	of	death	
in mice in this study, a category that includes lymphomas and his‐
tiocytic sarcomas. Immunohistochemistry was not performed to 
definitively distinguish between the two. No glycine effect was 
seen on the frequency of hematopoietic tumors in these end‐of‐life 
necropsies.
Glycine is considered a nonessential amino acid, because it can 
be	synthesized	by	several	pathways,	and	hence	dietary	intake	pro‐
vides only part of the glycine pool. The endogenous glycine pool is 
also	affected	by	glycine	clearance	pathways.	A	preliminary	life‐span	
study	in	rats	using	glycine	supplementation	(Brind,	2011)	was	orig‐
inally conceived as an approach to mimic the well‐established life‐
extending	effect	of	methionine	restriction	(Brown‐Borg	et	al.,	2014;	
Miller	et	al.,	2005;	Orentreich,	1993;	Richie	et	al.,	2004;	Sun,	2009).	
The strategy was based on the understanding that glycine is the only 
acceptor for methyl groups by the action of glycine‐N‐methyl trans‐
ferase	 (GNMT),	 and	 that	 in	 turn	GNMT	 represents	 the	only	 path‐
way	for	the	clearance	of	excess	methionine	in	mammals	(Luka	et	al.,	
2009).	Supplemental	glycine,	however,	was	found	(Brind,	2011)	not	
to reduce plasma methionine levels, in contrast to the 60% reduc‐
tion in plasma methionine levels seen in rats on a low methionine 
diet. This result suggested that elevated glycine levels, in plasma or 
tissues, might in themselves produce health benefits and increased 
longevity. Glycine receptors are gated chloride channels that hyper‐
polarize plasma membranes and can inhibit cell activation; although 
they were originally thought to be restricted to the nervous system, 
more	 recent	 work	 has	 demonstrated	 glycine	 receptors	 on	 many	
cell types, including macrophages of lung and liver, and platelets 
(Schemmer	et	al.,	2013;	Wheeler,	1999).	Glycine	promotes	chloride	
influx	 largely	 at	 concentrations	 (0.5–1	mM)	 that	 are	 considerably	
higher than those needed for protein synthesis and one‐carbon 
transfer reactions. Prevention of cell activation and depolarization 
by maintenance of resting membrane potentials may help to limit 
macrophage	activation	(Zhong	et	al.,	2003).
Anti‐inflammatory,	 anticancer,	 and	 other	 putative	 benefits	 of	
glycine supplementation have been demonstrated in rodent models 
(Alarcon‐Aguilar,	2008;	Wang	et	al.,	2013;	Yi,	Xu,	&	Allison,	2003),	
and one translational study noted benefits in human diabetes trials 
(Cruz,	2008).	A	small	pilot	study	had	documented	a	significant	lifes‐
pan	benefit	in	inbred	rats	(Brind,	2011),	but	our	current	study	pro‐
vides more definitive evidence by using a second species, by using 
genetically heterogeneous animals, by documenting significant ef‐
fects in both males and females, and by showing similar benefits at 
each of three independent test sites. The mechanism of effect is not 
yet	known	and	will	require	additional	targeted	work,	but	could	con‐
ceivably involve lowered inflammation in one or more tissue beds, 
or effects of glycine on CNS processes, or effects, direct or indirect, 
on multiple forms of lethal neoplastic disease. Consistent with these 
ideas, observational studies have documented lower glycine levels 
in	people	suffering	from	diabetes	and	prediabetes	(Guasch‐Ferré	et	
al.,	 2016),	 cardiovascular	 disease	 (Ding,	 2015),	 and	 hepatocellular	
carcinoma	 (Osman,	 2017).	 Similarly,	 a	 recent	 metabolomics	 study	
(Hartiala,	2016)	 reported	a	12%	decreased	 risk	of	coronary	artery	
disease	 (CAD)	 among	 female	 human	 subjects	 associated	with	 the	
genetic variant Rs715, which impairs function of the mitochondrial 
enzyme	carbamoyl	phosphate	synthase	(CPS).	Carbamoyl	phosphate	
synthase catalyzes the first step of the urea cycle, removing ammo‐
nia	derived	 largely	 from	glycine	 cleavage.	Women	with	 the	Rs715	
variant have elevated plasma glycine levels, which might potentially 
contribute	to	their	lower	risk	of	coronary	disease.
The present study provides support for the hypothesis that con‐
sumption of glycine in the normal diet may be suboptimal for lon‐
gevity, and that higher levels might be beneficial, perhaps through 
moderation of inflammatory processes. The limited data from the 
rat	study	(Brind,	2011)	suggest	that	higher	glycine	doses	might	not	
produce higher benefits, but it is possible that initiation of glycine 
supplementation at an earlier age might be worth testing.
We	considered	the	possibility	that	extended	longevity	in	the	gly‐
cine‐treated	mice	might	reflect	low	food	intake.	This	seems	unlikely,	
because male mice show extended longevity without small body 
size.	Food	intake	is	very	difficult	to	measure	accurately,	because	of	
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complications from food wastage into cage bedding, caloric loss in 
feces, and variability among mice in the same cage. In addition, small 
mice eat less food than large mice, because they have diminished the 
need for thermogenesis; thus, an association between size and food 
intake	does	not	demonstrate	a	causal	connection	in	either	direction.	
We	cannot,	however,	rule	out	the	possibility	that	glycine	supplemen‐
tation	might	have	led	to	low	food	intake	and	to	extended	longevity	in	
female mice. Incorporation of glycine into the diet lowers its calorie 
density	by	<1%,	which	is	unlikely	to	lead	to	any	alteration	in	nutri‐
tional status or health.
The ITP is committed to reporting the outcome of all longev‐
ity studies, including those of interventions that did not appear 
to produce health benefits. Three such agents were tested in the 
same	 cohort	 (C2014)	 that	 included	 the	 glycine‐supplemented	
mice.
TM5441	was	selected	for	testing	because	it	 is	an	orally	active,	
small‐molecule	 inhibitor	 of	 PAI‐1,	 the	 primary	 inhibitor	 of	 tissue	
and	urokinase	plasminogen	activators,	and	thus	a	primary	effector	
of	 fibrinolysis	 and	 extracellular	 proteolysis	 (Boe,	 2013).	 PAI‐1	 lev‐
els	increase	with	age	in	mice	and	humans	(Khan,	2017;	Testa	et	al.,	
2009;	Yamamoto	et	al.,	2002)	and	are	increased	by	obesity,	insulin	
resistance,	 and	 inflammation	 (Alessi	 &	 Juhan‐Vague,	 2006;	 Khan,	
2017).	PAI‐1	is	present	 in	atherosclerotic	plaques	and	accumulates	
with	age	 in	murine	heart	muscle	 (Sobel,	 Lee,	Pratley,	&	Schneider,	
2006).	PAI‐1	appears	to	contribute	to	common	cardiovascular	man‐
ifestations	 of	 aging.	 PAI‐1	 excess	 is	 prothrombotic,	 and	 PAI‐1	 ap‐
pears to be an important contributor to arteriosclerosis and vascular 
stiffness	(Lieb	et	al.,	2009).	A	recently	published	Mendelian	analysis	
concluded	that	PAI‐1	plays	a	causal	 role	 in	coronary	heart	disease	
(Song,	 2017).	 PAI‐1	 is	 elevated	 in	 the	 klotho	 (kl/kl)	mutant	mouse	
and in the BubR1H/H mutant, mice which some have interpreted as 
models	of	accelerated	aging,	and	administration	of	TM5441	extends	
median	lifespan	of	klotho	mice	(Eren	et	al.,	2014).	We	hypothesized	
that	inhibition	of	PAI‐1	by	TM5441	would	lead	to	extended	lifespan	
in	normal	mice,	 but	 found	no	evidence	 for	higher	 lifespan	 in	UM‐
HET3	mice	treated	from	11	months	of	age.
Inulin was selected for testing because it had shown preliminary 
evidence for lifespan benefit in a large‐scale screen using female 
B6C3F1 mice. In this unpublished screen, over 1,000 drugs and re‐
lated molecules were tested in parallel using a shared control group. 
Drugs	were	administered	from	5	months	of	age	at	doses	50%–100%	
of the maximum recommended therapeutic dose for human patients. 
In this survey, inulin at 600 ppm was found to extend mean and max‐
imal lifespan by 16%, with p = 0.06 for the mean value compared to 
control females. Inulin is a soluble fiber, derived from chicory root, 
that is metabolized by gut bacteria, and is hypothesized to promote 
host health by improvements in the balance of species within the gut 
microbial populations. There is some previous evidence that inulin 
can	extend	rat	 lifespan	 (Rozan	et	al.,	2008).	Our	own	data	did	not	
provide any evidence for health benefits of inulin when given from 
11	months	of	age	 to	male	or	 female	UM‐HET3	mice.	 It	 is	possible	
that	a	beneficial	effect	of	TM5441	or	 inulin	might	have	been	seen	
had we use a different dose, started at an earlier time, started at 
a later time, or discontinued exposure to the drug after a period of 
treatment.
Aspirin	was	selected	for	 testing	as	a	 follow‐up	to	our	previous	
report	(Strong	et	al.,	2008)	of	lifespan	extension	in	UM‐HET3	male	
mice given aspirin at 20 ppm from 4 months of age. In the original 
report, we found no effect of aspirin on female longevity, and the 
effect	on	male	longevity	(8%	increase	in	median,	p	=	0.01	by	log‐rank	
test)	represented	benefits	seen	at	the	two	sites	(UT	and	TJL)	in	which	
male controls were significantly shorter lived than at the third site 
(UM).	To	see	whether	we	could	obtain	 larger	and	more	consistent	
benefits, we tested mice at doses that were threefold and 10‐fold 
higher	than	the	dose	used	 in	the	original	 ITP	report.	We	found	no	
evidence for the benefit of either dose in male or female animals. 
While	it	is	possible	that	we	might	have	seen	a	benefit	for	60	ppm	or	
200	ppm	if	we	had	started	at	an	earlier	age	(4	months,	as	in	the	orig‐
inal	report),	and	possible	that	authentic	beneficial	effects	at	20	ppm	
are lost at the higher doses, our preferred interpretation is that the 
original report reflected a type I error and that aspirin does not re‐
liably confer increased lifespan in these genetically heterogeneous 
mice.
4  | METHODS
4.1 | Mouse husbandry
The ITP protocol for longevity studies has been described exten‐
sively	elsewhere	 (Miller	et	al.,	2014;	Strong,	2016),	with	details	on	
source	of	 food,	bedding,	cage	changes,	 light/dark	cycle,	and	other	
husbandry	details.	In	brief,	mice	are	bred	as	the	progeny	of	(BALB/
cByJ	×	C57BL/6J)F1	 mothers	 and	 (C3H/HeJ	×	DBA/2J)F1	 fathers,	
so that each mouse is genetically unique and a full sib to all other 
mice	with	 respect	 to	 segregating	nuclear	 alleles.	Mice	 are	 housed	
at three males or four females per cage from weaning, without re‐
placement as mice die at older ages. They are given free access to 
food	and	water.	Purina	5LG6	is	used	as	the	base	diet	from	weaning,	
with drugs and supplements given at the concentrations shown in 
Supporting	 Information	Table	S1.	Mice	are	weighed	at	 ages	6,	12,	
18, and 24 months, but are otherwise undisturbed. If fight wounds 
require that mice be removed for humane reasons, all the mice in the 
affected cage are removed from the study, so as not to enrich for 
dominant	or	nondominant	individuals.	Mice	that	are	removed	from	
the	study,	either	for	fighting	or	for	other	technical	reasons	(e.g.,	chip	
ID	dysfunction,	escape,	accidental	 injury),	are	treated	as	known	to	
be alive on the day of removal and lost to follow‐up at that point. 
Mice	are	inspected	daily,	and	those	which	are	deemed	to	be	unlikely	
to	live	for	more	than	another	24	hr,	based	on	a	symptom	checklist,	
are	euthanized	for	humane	reasons,	with	the	day	of	euthanasia	taken	
as the best estimate of the date of natural death for statistical pur‐
poses. Date of death is also recorded for those found dead. Sentinel 
mice are tested for antibodies against pathogenic viruses and for 
parasites, either annually or quarterly depending on the pathogen, 
and all such tests were negative at each test site throughout the pe‐
riod of this study.
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4.2 | Estimation of glycine, TM‐5441, aspirin, and 
salicylic acid in food and tissue samples
Glycine levels were measured in food, serum, and liver tissue using an 
LC/MS/MS	system	(a	Shimadzu	SIL	20A	HT	autosampler,	LC‐20AD	
pumps,	and	an	AB	Sciex	API	3200	tandem	mass	spectrometer	with	
turbo	 ion	spray).	Serum	standard	curves	were	obtained	by	spiking	
normal serum at concentrations from 5 to 160 μg/ml.	Liver	glycine	
concentrations were estimated in a similar way using sonicated tis‐
sues,	with	calibration	standards	between	63	and	1,000	ng/mg.	LC/
MS/MS	methods	for	quantitating	TM‐5441	in	serum	and	in	food	pel‐
lets	used	standards	purchased	from	Tocris	Bioscience	(Minneapolis,	
MN).	Estimation	of	 aspirin	 and	 salicylic	 acid	 levels	used	 standards	
purchased	from	Sigma	Chemical	Company	(St.	Louis,	MO).	We	were	
unable to develop an assay for inulin in serum, because inulin con‐
sists of a complex mixture of polysaccharides of different molecular 
sizes.
4.3 | Terminal necropsies
Mice	dying	(or	euthanized	when	terminally	ill)	were	fixed	using	a	pro‐
cess in which incisions were made in cranium, thorax, and abdomen, 
and the carcass immersed in 10% neutral‐buffered formalin, and 
then	kept	at	room	temperature	for	a	period	of	up	to	4	years.	Glycine‐
treated and control cases were then selected by a random number 
table, selecting 10 male and 10 female glycine‐treated mice from 
each	test	site,	plus	an	equal	number	of	control	mice.	Each	animal	was	
given a code so that the assessment of lesions could be conducted 
by a veterinary pathologist blinded to the treatment group, and 
the specimens were then shipped to the Geropathology Research 
Program	at	University	of	Washington	for	necropsy	and	histopatho‐
logical	analysis.	A	detailed	description	of	procedures	and	diagnostic	
criteria	is	given	in	the	Supplemental	Methods	section.
4.4 | Statistical testing
Drug	effects	on	lifespan	are	evaluated	by	the	log‐rank	test,	strati‐
fying by site, separately for males and females. For analyses com‐
bining	male	 and	 female	 survival	 data,	 the	 log‐rank	 test	 includes	
stratification by both sex and site. These data sets include mice 
that have died, mice removed for fighting or other cause, and mice 
still	 alive	at	 the	 time	of	evaluation.	Estimates	of	median	survival	
age and of the age at which 90% have died include only live and 
dead,	but	not	removed,	mice.	Hypotheses	about	survival	to	very	
old	 age	 are	 done	 by	 the	method	 of	Wang	 and	Allison	 (Wang	 et	
al.,	 2004),	 using	 Fisher's	 exact	 test.	 Effects	 of	 interventions	 on	
body weight are evaluated separately in each sex by a two‐factor 
ANOVA	(drug,	site,	and	interaction	terms),	with	the	p‐value for the 
drug	effect	 taken	as	 the	key	outcome.	For	 the	significance	 tests	
of group differences in the proportion of mice with specific forms 
of	 pathology,	we	 used	 the	 “prtest”	 (proportions	 test)	module	 of	
Stata, which computes a normally distributed z‐statistic as the 
difference between the two proportions divided by the standard 
error of the difference under the null hypothesis. For significance 
tests of graded pathology findings, we used the Student's t test. 
Significance	was	assigned	with	respect	to	the	arbitrary	benchmark	
of p = 0.05 in two‐sided tests, without adjustment for multiple 
comparisons.
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